NCT03208803View on ClinicalTrials.gov

Combination of JAK2 Inhibitor and Erythropoiesis-stimulating Agent in Myelofibrosis

CompletedOBSERVATIONAL

Enrollment

65

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions

Myelofibrosis; Anemia

All Listed Sponsors

lead

Centre Hospitalier Annecy Genevois

OTHER

NCT03208803 - Combination of JAK2 Inhibitor and Erythropoiesis-stimulating Agent in Myelofibrosis | Biotech Hunter | Biotech Hunter